ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Experimental: ZEN003694 + Talazoparib

ZEN003694: 48.0 mg daily (oral) in 28-day cycles
Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694

Drug: ZEN003694
ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
Drug: Talazoparib
Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 25, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments